Source comparison
Peptides for Fat Loss: Clinical Evidence Comparison
CJC-1295 + Ipamorelin GH secretagogue (GHRH + ghrelin mimetic) 11.4% visceral fat reduction over 16 weeks Preserved or increased (+1.2kg mean) Subcutaneous, 5 days/week 100mcg each before bed or fasted training AOD-9604 hGH fragment, beta-3 receptor agonist 2.
This comparison does not assign a generated winner or score.
- CJC-1295 + Ipamorelin
- GH secretagogue (GHRH + ghrelin mimetic)
- 11.4% visceral fat reduction over 16 weeks
- Preserved or increased (+1.2kg mean)
- Subcutaneous, 5 days/week
- 100mcg each before bed or fasted training
- AOD-9604
- hGH fragment, beta-3 receptor agonist
- 2.6kg fat loss over 12 weeks vs 0.8kg placebo
- Neutral
- Subcutaneous, daily
- 1mg/day, morning fasted injection
- Tesofensine
- Triple monoamine reuptake inhibitor
- 10.6% body weight, 95% from fat mass over 24 weeks
- Preserved
- Oral capsule, daily
- 0.5mg/day with meals
- MK-677
- Oral GH secretagogue (GHSR-1a agonist)
- 0.9kg fat loss + 1.1kg lean gain over 8 weeks
- Increased (+1.1kg)
- Oral, daily
- 25mg/day before bed
- Hexarelin
- Ghrelin receptor agonist (strong affinity)
- Comparable to CJC-1295 but 8–12 week cycles only
- 100–200mcg before training, cycled to prevent desensitization
- Professional Assessment
- GH secretagogues dominate the evidence base for fat loss with lean mass preservation. AOD-9604 is best for insulin-resistant populations. Tesofensine shows the largest total weight reduction but through appetite suppression rather than pure lipolysis. Protocols combining CJC-1295/ipamorelin with resistance training consistently outperform single-agent approaches.